280 related articles for article (PubMed ID: 18929237)
1. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Wani JH; John-Kalarickal J; Fonseca VA
Cardiol Clin; 2008 Nov; 26(4):639-48. PubMed ID: 18929237
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
3. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
4. DPP-4 inhibitors in clinical practice.
Palalau AI; Tahrani AA; Piya MK; Barnett AH
Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
[TBL] [Abstract][Full Text] [Related]
7. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Ahrén B
Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.
Flatt PR; Bailey CJ; Green BD
Front Biosci; 2008 May; 13():3648-60. PubMed ID: 18508462
[TBL] [Abstract][Full Text] [Related]
9. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
[TBL] [Abstract][Full Text] [Related]
10. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
11. [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Jermendy G
Orv Hetil; 2011 Sep; 152(37):1471-6. PubMed ID: 21893477
[TBL] [Abstract][Full Text] [Related]
12. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Gallwitz B
Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
[No Abstract] [Full Text] [Related]
13. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
14. DPP-4 inhibitors: what may be the clinical differentiators?
Gerich J
Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
16. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Pei Z
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
[TBL] [Abstract][Full Text] [Related]
17. DPP-4 inhibitors.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):517-33. PubMed ID: 18054733
[TBL] [Abstract][Full Text] [Related]
18. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
[TBL] [Abstract][Full Text] [Related]
19. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Ahrén B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
[TBL] [Abstract][Full Text] [Related]
20. Three new drugs for type 2 diabetes.
Drug Ther Bull; 2008 Jul; 46(7):49-52. PubMed ID: 18603639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
